CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Zentalis Pharmaceuticals - ZNTL CFD

    11.26
    0.36%
    0.18
    Low: 10.42
    High: 11.28
    Market Trading Hours* (UTC) Opens on Monday at 14:30

    Mon - Fri: 14:30 - 21:00

    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.18
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026235 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026235%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004012 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004012%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Zentalis Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 11.21
    Open* 10.42
    1-Year Change* -52.85%
    Day's Range* 10.42 - 11.28
    52 wk Range 9.56-31.46
    Average Volume (10 days) 1.43M
    Average Volume (3 months) 22.12M
    Market Cap 732.43M
    P/E Ratio -100.00K
    Shares Outstanding 70.77M
    Revenue N/A
    EPS -4.65
    Dividend (Yield %) N/A
    Beta 1.58
    Next Earnings Date Feb 28, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 1, 2023 11.25 0.24 2.18% 11.01 11.31 10.34
    Nov 30, 2023 11.21 0.60 5.66% 10.61 11.34 10.56
    Nov 29, 2023 10.53 0.23 2.23% 10.30 11.05 10.18
    Nov 28, 2023 10.36 0.22 2.17% 10.14 10.39 9.99
    Nov 27, 2023 10.34 -0.26 -2.45% 10.60 10.67 10.18
    Nov 24, 2023 10.76 0.56 5.49% 10.20 10.76 10.16
    Nov 22, 2023 10.33 -0.02 -0.19% 10.35 10.48 10.17
    Nov 21, 2023 10.24 -0.41 -3.85% 10.65 10.80 10.22
    Nov 20, 2023 10.75 -0.48 -4.27% 11.23 11.39 10.59
    Nov 17, 2023 11.31 0.36 3.29% 10.95 11.53 10.94
    Nov 16, 2023 11.12 -0.25 -2.20% 11.37 11.47 10.31
    Nov 15, 2023 11.65 0.37 3.28% 11.28 12.40 11.18
    Nov 14, 2023 11.68 0.76 6.96% 10.92 11.71 10.67
    Nov 13, 2023 10.20 0.67 7.03% 9.53 10.30 9.51
    Nov 10, 2023 9.79 0.11 1.14% 9.68 9.99 9.52
    Nov 9, 2023 9.90 -0.03 -0.30% 9.93 10.35 9.70
    Nov 8, 2023 9.94 0.24 2.47% 9.70 10.24 9.49
    Nov 7, 2023 10.13 -1.73 -14.59% 11.86 12.24 9.68
    Nov 6, 2023 12.35 -5.32 -30.11% 17.67 17.87 12.05
    Nov 3, 2023 17.80 1.52 9.34% 16.28 17.96 16.28

    Zentalis Pharmaceuticals Events

    Time (UTC) Country Event
    Wednesday, February 28, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Zentalis Pharmaceuticals Inc Earnings Release
    Q4 2023 Zentalis Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0.014
    Revenue 0 0.014
    Total Operating Expense 227.287 164.96 118.787 46.845 23.797
    Selling/General/Admin. Expenses, Total 54.553 40.941 33.886 8.459 4.876
    Research & Development 172.734 166.801 84.901 38.386 18.921
    Operating Income -227.287 -164.96 -118.787 -46.845 -23.783
    Interest Income (Expense), Net Non-Operating 5.987 0.401 0.683 0.498 0.355
    Other, Net -0.016 0
    Net Income Before Taxes -221.3 -164.559 -118.104 -46.363 -23.428
    Net Income After Taxes -220.831 -164.262 -118.548 -46.378 -23.432
    Minority Interest 0.307 7.368 0.707 0.715 2.365
    Net Income Before Extra. Items -236.806 -158.725 -117.841 -45.663 -21.067
    Net Income -236.806 -158.725 -117.841 -45.663 -21.067
    Income Available to Common Excl. Extra. Items -236.806 -158.725 -117.841 -45.663 -21.067
    Income Available to Common Incl. Extra. Items -236.806 -158.725 -117.841 -45.663 -21.067
    Diluted Net Income -236.806 -158.725 -117.841 -45.663 -21.067
    Diluted Weighted Average Shares 52.857 42.688 28.113 34.5015 34.5015
    Diluted EPS Excluding Extraordinary Items -4.48013 -3.71826 -4.19169 -1.32351 -0.61061
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -4.48013 -4.29754 -4.19169 -1.32351 -0.61061
    Unusual Expense (Income) 0 -42.782
    Equity In Affiliates -16.282 -1.831
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 103.916 64.953 51.754 54.193 63.461
    Selling/General/Admin. Expenses, Total 15.664 11.369 11.138 12.012 19.636
    Research & Development 88.252 48.584 40.616 42.181 43.825
    Operating Income -103.916 -64.953 -51.754 -54.193 -63.461
    Interest Income (Expense), Net Non-Operating 4.451 4.109 3.232 1.905 0.424
    Other, Net
    Net Income Before Taxes -99.465 -60.844 -48.522 -52.288 -63.037
    Net Income After Taxes -98.86 -60.952 -48.162 -52.129 -63.054
    Minority Interest 0.037 0.043 0.013 0.099 0.035
    Net Income Before Extra. Items -112.527 -63.219 -54.971 -54.401 -68.357
    Net Income -112.527 -63.219 -54.971 -54.401 -68.357
    Income Available to Common Excl. Extra. Items -112.527 -63.219 -54.971 -54.401 -68.357
    Income Available to Common Incl. Extra. Items -112.527 -63.219 -54.971 -54.401 -68.357
    Diluted Net Income -112.527 -63.219 -54.971 -54.401 -68.357
    Diluted Weighted Average Shares 60.79 59.277 58.134 56.807 51.117
    Diluted EPS Excluding Extraordinary Items -1.85108 -1.0665 -0.94559 -0.95765 -1.33727
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -1.85108 -1.01167 -0.94559 -0.95765 -1.33727
    Unusual Expense (Income) 0 5 0 0
    Equity In Affiliates -13.704 -2.31 -6.822 -2.371 -5.338
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 451.933 350.77 345.104 68.891 26.677
    Cash and Short Term Investments 437.371 339.887 338.505 67.246 25.154
    Cash & Equivalents 43.069 59.714 54.951 67.246 25.154
    Total Receivables, Net 6.382 0.004 0.417 0.14 0.917
    Accounts Receivable - Trade, Net 0.004 0.417 0.14 0.917
    Prepaid Expenses 7.521 10.636 6.182 1.505 0.606
    Total Assets 539.31 454.507 365.555 87.481 40.998
    Property/Plant/Equipment, Total - Net 50.078 52.839 3.619 2.836 0.26
    Property/Plant/Equipment, Total - Gross 52.138 53.631 3.869 3.003 0.316
    Accumulated Depreciation, Total -2.06 -0.792 -0.25 -0.167 -0.056
    Goodwill, Net 3.736 3.736 3.736 3.736 3.736
    Intangibles, Net 0 8.8 8.8 8.8
    Other Long Term Assets, Total 12.35 9.667 4.296 3.218 1.525
    Total Current Liabilities 56.647 43.944 28.601 14.897 6.208
    Accounts Payable 11.247 11.59 8.661 4.289 3.431
    Accrued Expenses 45.016 31.383 19.53 10.608 2.554
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 0.384 0.971 0.41 0 0.223
    Total Liabilities 105.507 90.553 56.973 25.881 16.228
    Total Long Term Debt 0 0 0 0 0
    Deferred Income Tax 0.853 1.622 2.48 2.463 2.463
    Minority Interest 0.221 0.528 24.795 6.821 7.536
    Other Liabilities, Total 47.786 44.459 1.097 1.7 0.021
    Total Equity 433.803 363.954 308.582 61.6 24.77
    Redeemable Preferred Stock 0 0 0 141.706 59.83
    Common Stock 0.059 0.045 0.041 2.887 2.27
    Retained Earnings (Accumulated Deficit) -596.365 -359.559 -200.834 -82.993 -37.33
    Total Liabilities & Shareholders’ Equity 539.31 454.507 365.555 87.481 40.998
    Total Common Shares Outstanding 59.2803 45.4908 41.0403 34.5015 34.5015
    Short Term Investments 394.302 280.173 283.554
    Additional Paid-In Capital 1031.46 723.593 509.339
    Unrealized Gain (Loss) -1.353 -0.125 0.036
    Other Current Assets, Total 0.659 0.243
    Long Term Investments 21.213 37.495
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 563.929 410.226 451.933 433.89
    Cash and Short Term Investments 552.986 392.519 437.371 421.726
    Cash & Equivalents 266.558 36.28 43.069 42.551
    Short Term Investments 286.428 356.239 394.302 379.175
    Total Receivables, Net 1.81 8.293
    Accounts Receivable - Trade, Net
    Prepaid Expenses 8.222 8.474 14.562 12.164
    Total Assets 621.444 489.342 539.31 529.193
    Property/Plant/Equipment, Total - Net 43.234 44.355 50.078 50.673
    Property/Plant/Equipment, Total - Gross 45.998 47.448 52.138 52.374
    Accumulated Depreciation, Total -2.764 -3.093 -2.06 -1.701
    Goodwill, Net 3.736 3.736 3.736 3.736
    Intangibles, Net
    Other Long Term Assets, Total 10.545 12.122 12.35 12.859
    Total Current Liabilities 51.759 56.358 56.647 54.061
    Accounts Payable 12.305 12.818 11.247 9.82
    Accrued Expenses 38.832 43.115 45.016 43.893
    Notes Payable/Short Term Debt 0 0 0 0
    Other Current Liabilities, Total 0.622 0.425 0.384 0.348
    Total Liabilities 98.303 103.855 105.507 100.689
    Total Long Term Debt 0 0 0 0
    Deferred Income Tax 0 0.756 0.853 1.225
    Minority Interest 0.141 0.178 0.221 0.234
    Other Liabilities, Total 46.403 46.563 47.786 45.169
    Total Equity 523.141 385.487 433.803 428.504
    Redeemable Preferred Stock 0 0 0 0
    Common Stock 0.07 0.059 0.059 0.057
    Additional Paid-In Capital 1295.52 1045.57 1031.46 972.111
    Retained Earnings (Accumulated Deficit) -772.111 -659.584 -596.365 -541.394
    Other Equity, Total -0.338
    Total Liabilities & Shareholders’ Equity 621.444 489.342 539.31 529.193
    Total Common Shares Outstanding 70.6037 59.4423 59.2803 57.0023
    Other Current Assets, Total 0.911 0.94 0 0
    Long Term Investments 0 18.903 21.213 28.035
    Unrealized Gain (Loss) -0.556 -1.353 -2.27
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -237.113 -166.093 -118.548 -46.378 -23.432
    Cash From Operating Activities -163.751 -154.093 -86.825 -39.143 -24.251
    Cash From Operating Activities 1.426 0.544 0.16 0.111 0.051
    Non-Cash Items 59.453 -5.101 23.702 0.617 0.308
    Cash Taxes Paid 0.012 0.02 0.018 0.015 0.004
    Changes in Working Capital 13.252 16.557 7.844 6.507 -1.178
    Cash From Investing Activities -114.18 -18.115 -284.832 -0.352 -0.227
    Capital Expenditures -2.548 -6.107 -0.758 -0.352 -0.227
    Cash From Financing Activities 261.043 178.521 360.439 81.83 9.472
    Financing Cash Flow Items 0 -1.146 18.424 -0.046 0
    Issuance (Retirement) of Stock, Net 261.043 179.667 342.015 81.876 9.472
    Net Change in Cash -16.888 6.313 -11.218 42.335 -15.006
    Deferred Taxes -0.769 0 0.017
    Other Investing Cash Flow Items, Total -111.632 -12.008 -284.074
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -63.262 -237.113 -182.129 -127.629 -59.237
    Cash From Operating Activities -49.283 -163.751 -126.422 -93.223 -50.196
    Cash From Operating Activities 0.36 1.426 1.067 0.692 0.344
    Non-Cash Items 17.735 59.453 45.371 34.074 12.044
    Changes in Working Capital -4.019 13.252 9.269 -0.36 -3.347
    Cash From Investing Activities 42.121 -114.18 -102.286 -122.304 19.796
    Capital Expenditures -2.548 -2.388 -0.728 -0.45
    Other Investing Cash Flow Items, Total 42.121 -111.632 -99.898 -121.576 20.246
    Cash From Financing Activities 0.373 261.043 211.302 210.713 1.258
    Financing Cash Flow Items 0 0
    Issuance (Retirement) of Stock, Net 0.373 261.043 211.302 210.713 1.258
    Net Change in Cash -6.789 -16.888 -17.406 -4.814 -29.142
    Deferred Taxes -0.097 -0.769
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Matrix Capital Management Company, LP Investment Advisor/Hedge Fund 19.7707 13959973 4760000 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 14.3315 10119378 1661800 2023-06-30 LOW
    Eventide Asset Management, LLC Investment Advisor 11.0666 7814039 936236 2023-09-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.9685 4920437 688558 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.0323 3553312 495870 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.4653 3152914 320891 2023-06-30 LOW
    Capital International Investors Investment Advisor 4.4297 3127758 0 2023-06-30 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 3.7516 2648978 482312 2023-06-30 LOW
    Avidity Partners Management LP Hedge Fund 3.3055 2334000 -595300 2023-06-30 HIGH
    Citadel Advisors LLC Hedge Fund 3.0156 2129296 799303 2023-06-30 LOW
    Decheng Capital Management III (Cayman) LLC Investment Advisor 2.9735 2099583 275000 2023-06-30 LOW
    Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 2.8583 2018234 531236 2023-06-30 LOW
    T. Rowe Price Investment Management, Inc. Investment Advisor 2.8316 1999354 -11055 2023-06-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 2.7028 1908444 -1451885 2023-06-30 LOW
    AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.8715 1321435 31139 2023-06-30 LOW
    PRIMECAP Management Company Investment Advisor 1.5737 1111150 -17770 2023-06-30
    Cormorant Asset Management, LP Hedge Fund 1.5508 1095000 1095000 2023-06-30 LOW
    Woodline Partners LP Hedge Fund 1.5507 1094974 -1070577 2023-06-30 HIGH
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.512 1067601 171676 2023-06-30 LOW
    Tybourne Capital Management (HK) Limited Hedge Fund 1.3617 961486 -670803 2023-06-30 MED

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Zentalis Pharmaceuticals Company profile

    About Zentalis Pharmaceuticals Inc

    Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Zentalis Pharmaceuticals Inc revenues was not reported. Net loss increased 35% to $158.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 88% to $145.9M (expense), Stock-based Compensation in R&D increase from $7.3M to $20.9M (expense), Selling, General & Administrative Expens increase of 31% to $23.7M (expense).

    Industry: Bio Therapeutic Drugs

    1359 Broadway, Suite 801
    NEW YORK
    NEW YORK 10018
    US

    Income Statement

    • Annual
    • Quarterly

    News

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023
    GBP

    UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

    UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

    10:48, 21 November 2023

    People also watch

    BTC/USD

    40,656.80 Price
    +2.260% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.64 Price
    +0.730% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    15,947.80 Price
    -0.300% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Oil - Crude

    73.76 Price
    -0.990% 1D Chg, %
    Long position overnight fee -0.0136%
    Short position overnight fee -0.0083%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading